V
vTv Therapeutics D
D
VTVT
20.390
USD
-1.12
(-5.21%)
مغلق
حجم التداول
4
الربح لكل سهم
-4
العائد الربحي
-
P/E
-7
حجم السوق
53,365,014
الأخبار المقالات
العنوان: vTv Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.